IP Library › Patent Application 15824641
Patent Application
App. No. 15/824,641

OSTEOPOROSIS ASSOCIATED MARKERS AND METHODS OF USE

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
15/824,641
Abstract

Disclosed are methods of identifying subjects with osteoporosis or osteopenia, subjects at risk for developing osteoporosis, osteopenia, and bone fractures, methods of evaluating the effectiveness of osteoporosis treatments in subjects with osteoporosis or osteopenia, and methods of selecting therapies for treating osteoporosis or osteopenia, using biomarkers.

Claims (8)

1 . A method for treating a human subject at risk, for developing osteoporosis or pre-osteoporosis, comprising:

a. measuring one or more OSTEORISKMARKERS present in a sample from the human subject; and

b. treating the subject with one or more bone mineral content-modulating drugs until altered levels of the one or more OSTEORISKMARKERS return to a value measured in one or more control human subjects at low risk for developing osteoporosis or pre-osteoporosis, or a value measured in one or more control subjects who show improvements in osteoporosis or pre-osteoporosis risk markers as a result of treatment with one or more bone mineral content-modulating drugs.

2 . The method of claim 1 , wherein the bone mineral content-modulating drugs comprise alendronate, risedronate, etidronate, pamidronate, ibandronate, clodronate, raloxifene, tamoxifen, toremifene, teriparatide, strontium ranelate, recombinant peptide fragments of parathyroid hormone, estrogen/progesterone replacement therapies, monoclonal antibodies, inhibitors of receptor activator of nuclear factor klB ligand (RANKL), inhibitors of cathepsin K, antagonists of integrin Avp3, calcitonin, calcium supplements and vitamin D supplements; and combinations thereof.

3 . The method of claim 1 , wherein the improvements in osteoporosis or preo-steoporosis risk markers as a result of treatment with one or more bone mineral content-modulating drugs comprise a reduction in body mass index (BMI), an increase in bone mass index, an increase in bone mineral density, or combinations thereof.

4 . The method of claim 3 , wherein the increase in bone mineral density is measured by a bone mineral density test.

5 . The method of claim 1 , wherein the baseline value comprises a reference value.

6 . The method of claim 5 , wherein the reference value comprises an index value, or is derived from one or more risk prediction algorithms or computed indices for osteoporosis or pre-osteoporosis